Oncimmune Regulatory News (ONC)

25 September 2018

Oncimmune Holdings plc

("Oncimmune" or the "Company")

GRANT OF OPTIONS

Nottingham, UK - 25 September 2018: Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and marketing of personalised immunodiagnostics for the screening, detection and care of cancer, today announces that on 25 September 2018, share options over 183,812 £0.01 ordinary shares of the Company (representing approximately 0.18% of the issued ordinary share capital) were awarded to US and UK employees under the Company's 2016 Share Option Plan (an amalgamation of the Company's 2005 and 2007 Share Option Plans) and the USA Incentive Stock Option Plan.

The options are subject to the rules of the 2016 Share Option Plan and the USA Incentive Stock Option Plan and vest in five equal annual parts, the first fifth vesting on 25 July 2019 and each year thereafter for a further four years. All these options are exercisable at 128.5 pence, being the mid-market price of the Company's ordinary shares at the close of day on 24 September 2018.

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Geoffrey Hamilton-Fairley, Vice Chairman

contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Ben Burnett

+44 (0)20 3829 5000

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

+44 (0)20 7332 2500

Berenberg (Joint Broker)

Toby Flaux, Alix Mecklenburg-Solodkoff

+44 (0)20 3207 7800

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

Oncimmune@consilium-comms.com

+44 (0)20 3709 5708

About Oncimmune

Oncimmune is a leader in the development, manufacture and marketing of personalised immunodiagnostics for the screening, detection and care of cancer. The Group has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 155,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK, Europe & Asia. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT®-Liver launched in May 2018 and further tests are in development.

Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information, visit www.oncimmune.com